STOCK TITAN
  1. Home
  2. News
  3. AUTL

Autolus Therapeutics plc - AUTL STOCK NEWS

Welcome to our dedicated news page for Autolus Therapeutics plc (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on Autolus Therapeutics plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Autolus Therapeutics plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Autolus Therapeutics plc's position in the market.

News
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
Rhea-AI Summary
Autolus Therapeutics plc (AUTL) announces that the FDA has accepted its Biologics License Application for obecabtagene autoleucel (obe-cel) for patients with relapsed/refractory Adult B-Cell Acute Lymphoblastic Leukemia, with a PDUFA goal date of November 16, 2024. The company is also on track to submit a marketing authorization application to the European Medicines Agency in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.89%
Tags
none
-
News
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
Rhea-AI Summary
Autolus Therapeutics plc (AUTL) appoints Robert W. Azelby to its Board of Directors, bringing over 30 years of biopharmaceutical leadership and commercial experience. Mr. Azelby's extensive experience in building successful biotech companies and commercializing products is expected to be invaluable as Autolus moves closer to commercializing its first product, obe-cel, with a recently submitted BLA filing. The appointment reflects the company's strategic focus on leveraging strengths and transitioning from a development stage to a commercial company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
management
-
News
Autolus Therapeutics Announces Changes to its Board of Directors
Rhea-AI Summary
Autolus Therapeutics plc (Nasdaq: AUTL) appoints Elisabeth Leiderman, M.D. to the Board of Directors and announces the resignation of Kapil Dhingra, M.D. from the Board and chair of the Nominating and Corporate Governance Committee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
management
News
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Rhea-AI Summary
Autolus Therapeutics plc (Nasdaq: AUTL) announced data presentations at the American Society of Hematology (ASH) Annual Meeting, showing positive results from the FELIX Phase Ib/II study with obe-cel in relapsed/refractory adult B-ALL, long-term remissions with obe-cel, and initial data from the MCARTY Phase I study in multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
Rhea-AI Summary
Autolus Therapeutics plc (AUTL) submits BLA for obe-cel in r/r adult B-cell Acute Lymphoblastic Leukemia, plans to submit MAA to EMA in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
News
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
Rhea-AI Summary
Autolus Therapeutics plc (Nasdaq: AUTL) will host an in-person and webcast event on Sunday, December 10, 2023, to review key data from ongoing clinical studies. The event will feature a presentation by Dr. Claire Roddie and Dr. Christian Itin, focusing on the pooled analysis of the FELIX Phase Ib/II study, ALLCAR19 extension, and initial data from the AUTO8 MCARTY Phase I Study. The company will also provide webcast registration and access to presentation materials after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
conferences
News
Autolus Therapeutics announces participation in upcoming conferences
Rhea-AI Summary
Autolus Therapeutics plc (Nasdaq: AUTL) will be participating in three upcoming conferences in November. These conferences include the Truist Securities BioPharma Symposium Panel, the Jefferies London Healthcare Conference Fireside Chat, and the Piper Sandler 35th Annual Healthcare Conference Fireside Chat. Autolus Therapeutics' Chief Executive Officer, Dr Christian Itin, will be presenting at all three events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.54%
Tags
conferences
-
News
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
Rhea-AI Summary
Autolus Therapeutics plc announces the online publication of four abstracts submitted to the American Society of Hematology (ASH) Annual Meeting. The abstracts include data from clinical trials of obe-cel in relapsed/refractory B-ALL and multiple myeloma, demonstrating high rates of complete remission and a favorable safety profile. The company will also present data on the robustness of obe-cel's manufacturing process. The ASH Annual Meeting will be held from December 9 to 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.92%
Tags
conferences clinical trial
-
News
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Rhea-AI Summary
Autolus Therapeutics plc announced its operational and financial results for the quarter ended September 30, 2023. The company is on track to submit a Biologics License Application (BLA) for its potentially transformational treatment, Obe-cel, for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia (ALL) to the US FDA by the end of 2023. The company also provided updates on clinical data, commercial manufacturing facility progress, and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.92%
Tags
earnings
News
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
Rhea-AI Summary
Autolus Therapeutics to hold virtual event to discuss CAR T strategy in autoimmune diseases and Phase 1 study in systemic lupus erythematosus (SLE)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
conferences
Stock AUTL logo
Autolus Therapeutics plc

Nasdaq:AUTL

AUTL Rankings

#2263 Ranked by Market Cap
#2489 Ranked by Stock Gains
N/A Ranked by Dividends

AUTL Stock Data

1.29B
91.18M
18.04%
53.51%
1.57%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United Kingdom
58 Wood Lane

About AUTL

autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.